Workflow
生物医药产业提质升级
icon
Search documents
聚焦产业提质升级 北上协《股东来了》系列活动走进三家生物医药企业
Zheng Quan Ri Bao· 2025-09-23 16:33
Group 1 - The "Shareholders Are Coming" series of events organized by the Beijing Listed Companies Association aims to protect investor rights and facilitate communication between investors and listed companies [1][4] - The events featured three listed companies in the biopharmaceutical sector: Sanyuan Gene, China Pharmaceutical, and Ganli Pharmaceutical, showcasing their strengths in technological innovation and industry upgrades [2][3] Group 2 - Sanyuan Gene is a leading enterprise in the field of gene engineering drugs, with its main product being human interferon α1b, which is China's first gene engineering drug with independent intellectual property rights [2][5] - China Pharmaceutical has become an important platform for the China General Technology Group, focusing on an integrated development model in the pharmaceutical and medical device sectors, covering the entire industry chain from cultivation to international trade [3][5] - Ganli Pharmaceutical has achieved significant market competitiveness, ranking first in the procurement agreement volume for insulin analogs in 2024, and is actively expanding into the medical device sector [3][5] Group 3 - The series of events provided a platform for investors to engage with company management on key topics such as the development prospects of the biopharmaceutical industry and corporate strategies [4][5] - Company executives shared insights on their operational data, business models, and the challenges faced, emphasizing the importance of transparent communication with investors [5]
加大高质量科技供给和政策支持着力推动生物医药产业提质升级
Group 1 - The Chinese government emphasizes the importance of accelerating the development of the biopharmaceutical industry, focusing on high-quality technological supply and policy support to enhance innovation and produce more effective drugs [1][2] - The government aims to strengthen original innovation and tackle key core technologies, leveraging both government and market resources to foster a collaborative innovation environment [2] - There is a significant market potential for the health industry in China, with a strong emphasis on the development of innovative drugs and the need for timely identification of high clinical value projects [1][2] Group 2 - The government encourages the establishment of comprehensive support systems for biopharmaceutical innovation, including one-stop R&D solutions and collaboration between industry, academia, and research [2] - The integration of artificial intelligence in various stages of drug development, clinical trials, and production is highlighted as a means to enhance industry development [2] - The government also aims to promote the modernization and industrialization of traditional Chinese medicine by applying modern scientific theories and technologies [2]
李强在北京调研生物医药产业发展时强调 加大高质量科技供给和政策支持 着力推动生物医药产业提质升级
Xin Hua She· 2025-08-20 14:28
李强在北京调研生物医药产业发展时强调,加大高质量科技供给和政策支持,着力推动生物医药产业提 质升级。 (文章来源:新华社) ...